Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in Pediatric r/r B-NHL (BIANCA)
NCT03610724Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Jul 2021
- Modality
- CAR-T Cells
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B-cell non-Hodgkin lymphoma, sponsored by Novartis. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03610724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610724.